Anavex Life Sciences Corp (AVXL)

[falconer66a]

Be Assured, Anavex Knows — By Themselves

I'd be shocked if anyone from AVXL is looking at investors hub for perspective/ideas for follow-up/testing, or for scientific advice. Hopefully, they are ambitiously making advances in the areas you put forward, but, not so sure.

Don't be shocked. No one at Anavex knows or cares about who I am or what I post on some obscure internet message board.

But like people at Anavex, I'm a biologist who knows and does innovative biological research. I'm familiar with standard research protocols and approaches investigating toxicity, mutations, organismal development, genetics, etc. Virtually all competent research biologists familiar with the published data on Anavex's sigma-1 receptor agonists will raise the questions I have concerning future and additional applications for Anavex's proprietary molecules.

It's the process of informed innovation. Most companies in various technologies, but especially in pharmaceuticals, depend on and profoundly support informed innovation. Otherwise, they go out of business.

For example, at Anavex, years back, when the company was still trying to "figure things out," when they discovered that their molecule was actually a sigma-1 receptor ligand; that the molecule actually attached to and changed the sigma-1 receptor, jumped up and down, proclaiming, "Wow! That's it! Our molecule actually sticks to the sigma-1 receptor. Nobody knew that. Now, we do! We got this all figured out now. Ain't we great?"

But, no. If your company is doing simple chemistry, that discovery might have been the end of any needed or productive research. Good enough. But Anavex will be selling chemicals that reside in the body, even cross the blood/brain barrier and get into the cytosol, the fluids inside cells. What happens, good and bad, in there must be understood.

One early question. Is Anavex 2-73, now blarcamesine, mutagenic? Does it cause mutations? One can’t go the FDA for a drug’s approval without showing the measured mutagenicity of the proposed drug. There are standard tests for this; Anavex has certainly had them done on all of their drugs.

But when blarcamesine was tested for mutagenicity in murines, lab rodents, it might well have been discovered that not only was the drug non-mutagenic, didn’t cause mutations, but the rodents dosed with the drug actually lived longer, and with better health, than the comparative control animals who didn't get the drug. With such a finding, all of what I’ve conjectured would be tested for. There are strains of lab mice and rats that with particular diets or malnutrition that are particularly prone to genetic pathologies. Blarcamesine may reduce those developmental anomalies. Prophylaxis.

Testing for toxicity or mutagenicity of developmental defects (teratogenicity) is standard and required in drug development research. From any or all of that, Anavex has surely discovered the many prophylactic outcomes induced by their molecules. The testing is done in lab animals, not humans; is not inordinately expensive.

Anavex knows.